5TSU | pdb_00005tsu

Active conformation for Engineered human cystathionine gamma lyase (E59N, R119L, E339V) to depleting methionine

  • Classification: LYASE
  • Organism(s): Homo sapiens
  • Expression System: Escherichia coli BL21
  • Mutation(s): Yes 

  • Deposited: 2016-10-31 Released: 2017-10-11 
  • Deposition Author(s): Yan, W., Zhang, Y.
  • Funding Organization(s): National Institutes of Health/National Cancer Institute (NIH/NCI), National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), Welch Foundation

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 
    0.202 (Depositor), 0.205 (DCC) 
  • R-Value Work: 
    0.171 (Depositor), 0.176 (DCC) 
  • R-Value Observed: 
    0.172 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 5TSU

Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history

Literature

Structural Snapshots of an Engineered Cystathionine-gamma-lyase Reveal the Critical Role of Electrostatic Interactions in the Active Site.

Yan, W.Stone, E.Zhang, Y.J.

(2017) Biochemistry 56: 876-885

  • DOI: https://doi.org/10.1021/acs.biochem.6b01172
  • Primary Citation Related Structures: 
    5TSU, 5TT2

  • PubMed Abstract: 

    Enzyme therapeutics that can degrade l-methionine (l-Met) are of great interest as numerous malignancies are exquisitely sensitive to l-Met depletion. To exhaust the pool of methionine in human serum, we previously engineered an l-Met-degrading enzyme based on the human cystathionine-γ-lyase scaffold (hCGL-NLV) to circumvent immunogenicity and stability issues observed in the preclinical application of bacterially derived methionine-γ-lyases. To gain further insights into the structure-activity relationships governing the chemistry of the hCGL-NLV lead molecule, we undertook a biophysical characterization campaign that captured crystal structures (2.2 Å) of hCGL-NLV with distinct reaction intermediates, including internal aldimine, substrate-bound, gem-diamine, and external aldimine forms. Curiously, an alternate form of hCGL-NLV that crystallized under higher-salt conditions revealed a locally unfolded active site, correlating with inhibition of activity as a function of ionic strength. Subsequent mutational and kinetic experiments pinpointed that a salt bridge between the phosphate of the essential cofactor pyridoxal 5'-phosphate (PLP) and residue R62 plays an important role in catalyzing β- and γ-eliminations. Our study suggests that solvent ions such as NaCl disrupt electrostatic interactions between R62 and PLP, decreasing catalytic efficiency.


  • Organizational Affiliation
    • Department of Molecular Biosciences and ‡Institute for Cellular and Molecular Biology, The University of Texas at Austin , Austin, Texas 78712, United States.

Macromolecule Content 

  • Total Structure Weight: 373.78 kDa 
  • Atom Count: 24,978 
  • Modeled Residue Count: 3,077 
  • Deposited Residue Count: 3,376 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Cystathionine gamma-lyase
A, B, D, F, G
A, B, D, F, G, H
422Homo sapiensMutation(s): 3 
Gene Names: CTH
EC: 4.4.1.1 (PDB Primary Data), 4.4.1.2 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P32929 (Homo sapiens)
Explore P32929 
Go to UniProtKB:  P32929
PHAROS:  P32929
GTEx:  ENSG00000116761 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP32929
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Cystathionine gamma-lyase
C, E
422Homo sapiensMutation(s): 3 
Gene Names: CTH
EC: 4.4.1.1 (PDB Primary Data), 4.4.1.2 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P32929 (Homo sapiens)
Explore P32929 
Go to UniProtKB:  P32929
PHAROS:  P32929
GTEx:  ENSG00000116761 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP32929
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
LPI

Query on LPI



Download:Ideal Coordinates CCD File
L [auth C],
N [auth E]
N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-L-methionine
C13 H21 N2 O7 P S
TZGVKKRKUOYYOG-NSHDSACASA-N
MET

Query on MET



Download:Ideal Coordinates CCD File
I [auth A]METHIONINE
C5 H11 N O2 S
FFEARJCKVFRZRR-BYPYZUCNSA-N
CYS

Query on CYS



Download:Ideal Coordinates CCD File
O [auth F],
P [auth G],
Q [auth H]
CYSTEINE
C3 H7 N O2 S
XUJNEKJLAYXESH-REOHCLBHSA-N
SO4

Query on SO4



Download:Ideal Coordinates CCD File
J [auth A],
K [auth B],
M [auth D]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
LLP
Query on LLP
A, B, D, F, G
A, B, D, F, G, H
L-PEPTIDE LINKINGC14 H22 N3 O7 PLYS

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free:  0.202 (Depositor), 0.205 (DCC) 
  • R-Value Work:  0.171 (Depositor), 0.176 (DCC) 
  • R-Value Observed: 0.172 (Depositor) 
Space Group: P 2 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 111.889α = 90
b = 163.683β = 90
c = 181.099γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesCA154754
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesGM104896
Welch FoundationUnited StatesF-1778

Revision History  (Full details and data files)

  • Version 1.0: 2017-10-11
    Type: Initial release
  • Version 1.1: 2019-11-27
    Changes: Author supporting evidence
  • Version 1.2: 2023-10-04
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.3: 2023-11-15
    Changes: Data collection
  • Version 1.4: 2024-12-25
    Changes: Advisory, Derived calculations, Structure summary